
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Supplements and Featured Publications
over 24 years ago
Statin Pharmacology May Have Important Clinical Implicationsover 24 years ago
Role of hs-CRP in Cardiovascular Risk Predictionover 24 years ago
Role of managed care in implementing NCEP-ATP III guidelinesover 24 years ago
Aggressive Lipid Reduction Provides Additional Clinical Benefit





